MyChesCo on MSN9h
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab
Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...
ksn.com10h
Ellsworth woman raising awareness to rare neuromuscular disease
ELLSWORTH, Kan. (KSNW) – A woman from Ellsworth is navigating life with a rare neuromuscular disease. Tina Bruning learned of her diagnosis of generalized myasthenia gravis, or gMG, in May 2021. A ...
The American Journal of Managed Care3d
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...
Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...